ScreenPoint Medical Raises €11.9 Million in New Funding
ScreenPoint Medical, a company based in Nijmegen, Netherlands, has successfully secured €11.9 million in its latest funding round. This round was led by Insight Partners, with participation from Siemens Healthineers. ScreenPoint Medical specializes in AI solutions for breast imaging, aiming to improve early detection and optimize workflows for reading both 3D and 2D mammograms.
Company Overview
Founded in 2014, ScreenPoint Medical emerged as a spin-off from Radboud University Medical Centre. It was established by Professors Nico Karssemeijer and Sir Michael Brady. The company focuses on developing AI-based technology to enhance breast cancer detection and provide more personalized care options. The main product, Transpara, is an advanced AI software suite that aids radiologists in analyzing mammograms with greater accuracy and efficiency.
Leadership and Vision
Pieter Kroese, the CEO of ScreenPoint Medical, leads the company in its mission to advance breast cancer diagnosis and care. Under his leadership, the company has continued to push the boundaries of AI technology in medical imaging, striving to reduce uncertainty and improve diagnostic precision.
Strategic Use of Funds
The newly acquired funds will be utilized to drive product innovation and expand ScreenPoint Medical's presence in international markets. The goal is to strengthen its position in the field of breast cancer diagnosis and care, leveraging AI to advance the future of medical imaging.
This funding round reflects growing confidence in AI's role in healthcare, particularly in enhancing the accuracy and efficiency of cancer detection. ScreenPoint Medical's efforts are pivotal in supporting radiologists with cutting-edge tools that improve patient outcomes and streamline the diagnostic process.